Welcome

Welcome to the Theravet investors website,

Here you will find all the financial information dedicated to shareholders and investors

12/06/2023 - 07:30

TheraVet reports further achievements on its Osteosarcoma Program

11/23/2023 - 07:30

Launch of BIOCERA-VET® Canine Osteosarcoma Study conducted by the prestigious University of Florida

11/20/2023 - 18:00

TheraVet announces the setting up of an equity-linked financing facility and updates on its financing strategy

11/08/2023 - 07:30

Significant Sales Progression for BIOCERA-VET® in Q3 2023

10/25/2023 - 07:30

TheraVet announces the appointment of a Chief Financial Officer to reinforce its global financing and cost control strategy

10/18/2023 - 07:30

Increasingly successful attendance in major ortho EU & US conferences and North America launch of BIOCERA-VET COMBO-CLEAN

10/11/2023 - 07:30

BIOCERA-VET in Horse Bone Cysts Highlighted at an International Equine Conference in the USA

09/27/2023 - 07:30

Patient recruitment phase successfully completed in BIOCERA-VET fracture revision surgery study in toy dogs

09/06/2023 - 07:30

TheraVet reports its 2023 half-year results and provides an update on the development of its activities

07/11/2023 - 07:30

TheraVet provides an update on its 2023 half-year development and portfolio strategy

06/15/2023 - 07:30

TheraVet announces 300% increase in participating Centers in the Osteosarcoma Program since its initiation 6 months ago

05/31/2023 - 07:30

TheraVet announces the commercial launch of a local and sustained antibiotic releasing bone substitute

05/04/2023 - 07:30

TheraVet continues the assessment of BIOCERA-VET in a new clinical program

04/25/2023 - 07:30

TheraVet reports Full-Year 2022 Financial Results and provides the preparatory documents for the General Assembly of June 1st, 2023

04/06/2023 - 07:30

TheraVet launches its Osteosarcoma Reference Centers program

03/28/2023 - 07:30

TheraVet updates on its development and portfolio strategy

02/21/2023 - 07:30

TheraVet signs an international distribution agreement for BIOCERA-VET® covering 24 countries

02/15/2023 - 17:45

TheraVet announces the start of the assessment of BIOCERA-VET® in horse bone cyst

12/12/2022 - 07:30

TheraVet optimizes its commercial strategy in France with a new distribution agreement for its BIOCERA-VET® range

12/07/2022 - 07:30

BIOCERA-VET® nominated for the Veterinary Innovation Award (AFVAC 2022)

09/26/2022 - 07:30

TheraVet announces an exclusive distribution agreement for BIOCERA-VET in the USA

09/19/2022 - 07:30

TheraVet announces its participation in the 2022 ESVOT Congress with 3 scientific communications

09/09/2022 - 07:30

TheraVet reports its 2022 half-year results and provides an update on the development of its activities

06/30/2022 - 17:45

TheraVet provides its 2022 first half-year operational update

06/30/2022 - 07:30

TheraVet annonces the commercial launch of its BIOCERA-VET product line in the United States of America

06/02/2022 - 07:30

TheraVet annonces the commercial launch of the most comprehensive line of bone substitutes in the veterinary market

05/30/2022 - 07:30

TheraVet signs a distribution agreement with Nuzoa, a leading Spanish company in the distribution of veterinary products and services

05/12/2022 - 07:30

General Meeting of June 2, 2022: availability of preparatory documents

05/10/2022 - 07:30

TheraVet signs an important distribution agreement with the orthopaedics & surgical instrumentation distributor, Veterinary Instrumentation

04/06/2022 - 07:30

TheraVet reports Full Year 2021 Financial Results and confirms its ambitious development and commercial plans for 2022

03/28/2022 - 07:30

Market-making agreement with Banque Rothschild

03/15/2022 - 07:30

Commercial launch of BIOCERA-VET® in United Kingdom and Ireland

02/07/2022 - 07:30

TheraVet broadens its bone subtitutes portfolio with an innovative line of biological bone grafts

02/04/2022 - 07:30

Positive results of BIOCERA-VET®-Bone Surgery presented at the Annual Conference of the US Veterinary Orthopedic Society and confirmed on a larger patients cohort

01/25/2022 - 07:30

TheraVet provides its 2021 second half operational update

01/18/2022 - 07:30

TheraVet strengthens its sales organisation in France by signing an important distribution agreement for BIOCERA-VET®

01/10/2022 - 17:45

TheraVet announces the initiation of coverage of its stock by Degroof Petercam

12/16/2021 - 07:30

TheraVet is strengthening its corporate governance with the appointment of three new independent board members

12/09/2021 - 07:30

Commercial launch of BIOCERA-VET® for canine osteosarcoma in Belgium, France and The Netherlands

11/22/2021 - 17:45

TheraVet broadens significantly its BIOCERA-VET® product line through major distribution and research agreements

11/15/2021 - 07:30

TheraVet announces positive safety and efficacy results for BIOCERA-VET® in canine osteosarcoma

11/09/2021 - 07:30

TheraVet announces the signing of a research contract with Degroof Petercam

11/03/2021 - 07:30

TheraVet expands its bone substitutes product line

10/26/2021 - 07:30

First patients treated with BIOCERA-VET® Bone Surgery in the United States of America

10/21/2021 - 07:30

Commercial launch of BIOCERA-VET® in France and The Netherlands

09/22/2021 - 17:45

TheraVet announces its 2021 half-year results and provides an update on the development of its activities

09/10/2021 - 07:30

TheraVet announces the launch of the pivotal European multicentric clinical study of VISCO-VET in canine osteoarthritis

09/08/2021 - 07:30

TheraVet announces positive safety and efficacy results for VISCO-VET in canine osteoarthritis

09/01/2021 - 07:30

TheraVet announces the appointment of Veerle Zonnekeyn as Director of Regulatory Affairs

07/07/2021 - 07:30

TheraVet provides its Half-Year operational update of 2021

07/02/2021 - 07:30

TheraVet extends the use of BIOCERA-VET to a new curative approach of osteosarcoma in dogs through an innovative and multidisciplinary management

06/30/2021 - 07:30

TheraVet announces its 2021 Financial Calendar

06/11/2021 - 18:00

TheraVet: successful IPO on Euronext Growth® Paris et Brussels

05/26/2021 - 07:00

TheraVet lance son introduction en bourse sur Euronext Growth® Bruxelles et Paris (French only)

04/27/2021 - 07:30

BIOCERA-VET: a promising alternative to autologous bone graft in canine arthrodesis

04/01/2021 - 07:30

TheraVet announces the commercial launch of BIOCERA-VET

03/04/2021 - 07:30

Positive results of a single intra-articular injection of VISCO-VET in canine osteoarthritis

01/26/2021 - 07:30

Positive results in canine cranial cruciate ligament deficiency

12/10/2020 - 07:30

TheraVet raises 4 M€ to accelerate the development of its two veterinary products

06/15/2020 - 07:30

TheraVet completes first regulatory milestones for the US registration (NADA) of VISCO-VET in canine osteoarthritis

11/07/2019 - 07:30

TheraVet starts its US operations in its Texas-based subsidiary

All press releases

Madam Sir Invalid Input

* Required fields

Invalid Input

Entrée non valide